Literature DB >> 35272297

Understanding Sociodemographic Disparities in Maternal-Fetal Surgery Study Participation.

Abigail Wilpers1,2,3,4, Anna Y Lynn5, Barbara Eichhorn3,6, Amy B Powne3,7, Megan Lagueux3,8, Janene Batten9, Mert Ozan Bahtiyar4, Cary P Gross1,10.   

Abstract

BACKGROUND/
PURPOSE: Although maternal-fetal surgery to treat fetal anomalies such as spina bifida continues to grow more common, potential health disparities in the field remain relatively unexamined. To address this gap, we identified maternal-fetal surgery studies with the highest level of evidence and analyzed the reporting of participant sociodemographic characteristics and representation of racial and ethnic groups.
METHODS: We conducted a systematic review of the scientific literature using biomedical databases. We selected randomized control trials (RCTs) and cohort studies with comparison groups published in English from 1990 to May 5, 2020. We included studies from across the globe that examined the efficacy of fetal surgery for twin-twin transfusion syndrome (TTTS), obstructive uropathy, congenital diaphragmatic hernia (CDH), myelomeningocele (MMC), thoracic lesions, cardiac malformations, or sacrococcygeal teratoma. We determined the frequency of reporting of age, gravidity/parity, race, ethnicity, education level, language spoken, insurance, income level, and relationship status. We identified whether sociodemographic factors were used as inclusion or exclusion criteria. We calculated the racial and ethnic group representation for studies in the USA using the participation-to-prevalence ratio (PPR).
RESULTS: We included 112 studies (10 RCTs, 102 cohort) published from 1990-1999 (8%), 2000-2009 (30%), and 2010-2020 (62%). Most studies were conducted in the USA (47%) or Europe (38%). The median sample size was 58. TTTS was the most common disease group (37% of studies), followed by MMC (23%), and CDH (21%). The most frequently reported sociodemographic variables were maternal age (33%) and gravidity/parity (20%). Race and/or ethnicity was only reported in 12% of studies. Less than 10% of studies reported any other sociodemographic variables. Sociodemographic variables were used as exclusion criteria in 13% of studies. Among studies conducted in the USA, White persons were consistently overrepresented relative to their prevalence in the US disease populations (PPR 1.32-2.11), while Black or African-American, Hispanic or Latino, Asian, American-Indian or Alaska-Native, and Native-Hawaiian or other Pacific Islander persons were consistently underrepresented (PPR 0-0.60).
CONCLUSIONS: Sociodemographic reporting quality in maternal-fetal surgery studies is poor and inhibits examination of potential health disparities. Participants enrolled in studies in the USA do not adequately represent the racial and ethnic diversity of the population across disease groups.
© 2022 S. Karger AG, Basel.

Entities:  

Keywords:  Fetal therapy; Health disparities; Health equity; Maternal-fetal surgery

Mesh:

Year:  2022        PMID: 35272297      PMCID: PMC9117502          DOI: 10.1159/000523867

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.208


  141 in total

1.  In utero repair of myelomeningocele: a comparison of endoscopy and hysterotomy.

Authors:  J P Bruner; N B Tulipan; W O Richards; W F Walsh; F H Boehm; E K Vrabcak
Journal:  Fetal Diagn Ther       Date:  2000 Mar-Apr       Impact factor: 2.587

2.  Amnioreduction versus septostomy in twin-twin transfusion syndrome.

Authors:  J R Johnson; K Q Rossi; R W O'Shaughnessy
Journal:  Am J Obstet Gynecol       Date:  2001-11       Impact factor: 8.661

3.  Impact of maternal-fetal surgery for myelomeningocele on the progression of ventriculomegaly in utero.

Authors:  Amy Adelberg; Angela Blotzer; Gary Koch; Rachael Moise; Nancy Chescheir; Kenneth J Moise; Honor Wolfe
Journal:  Am J Obstet Gynecol       Date:  2005-09       Impact factor: 8.661

4.  Surgical management of twin reversed arterial perfusion sequence.

Authors:  Rubén A Quintero; Ramen H Chmait; Takeshi Murakoshi; Zofia Pankrac; Malgorzata Swiatkowska; Patricia W Bornick; Mary H Allen
Journal:  Am J Obstet Gynecol       Date:  2006-04       Impact factor: 8.661

5.  Evidence and patterns in lung response after fetal tracheal occlusion: clinical controlled study.

Authors:  Mieke M Cannie; Jacques C Jani; Frederik De Keyzer; Karel Allegaert; Steven Dymarkowski; Jan Deprest
Journal:  Radiology       Date:  2009-06-09       Impact factor: 11.105

6.  Laparoscopy-assisted fetoscopy for laser surgery in twin-twin transfusion syndrome with anterior placentation.

Authors:  R Papanna; A Johnson; R T Ivey; O O Olutoye; D Cass; K J Moise
Journal:  Ultrasound Obstet Gynecol       Date:  2010-01       Impact factor: 7.299

7.  In vivo evidence by magnetic resonance volumetry of a gestational age dependent response to tracheal occlusion for congenital diaphragmatic hernia.

Authors:  Katika Nawapun; Mary Patrice Eastwood; Daysi Diaz-Cobos; Julio Jimenez; Michael Aertsen; Olga Gomez; Filip Claus; Eduard Gratacós; Jan Deprest
Journal:  Prenat Diagn       Date:  2015-09-29       Impact factor: 3.050

8.  Sociodemographic attributes and spina bifida outcomes.

Authors:  Michael S Schechter; Tiebin Liu; Minn Soe; Mark Swanson; Elisabeth Ward; Judy Thibadeau
Journal:  Pediatrics       Date:  2015-03-16       Impact factor: 7.124

9.  Prediction of neonatal respiratory function and pulmonary hypertension in fetuses with isolated congenital diaphragmatic hernia in the fetal endoscopic tracleal occlusion era: a single-center study.

Authors:  Elisa Done; Anne Debeer; Leonardo Gucciardo; Tim Van Mieghem; Paul Lewi; Roland Devlieger; Luc De Catte; Liesbeth Lewi; Karel Allegaert; Jan Deprest
Journal:  Fetal Diagn Ther       Date:  2014-11-08       Impact factor: 2.587

10.  Morbidity and cost burden of prenatal myelomeningocele repair.

Authors:  Stefanie Riddle; Robert Huddle; Foong-Yen Lim; Charles Stevenson; Kristin Dean; Karen Sparling; Matthew Fenchel; Kurt Schibler
Journal:  J Matern Fetal Neonatal Med       Date:  2019-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.